BriaCell Therapeutics Corp. — Form 10-Q Summary
Reporting period: Three months ended October 31, 2023, the company’s first quarter of fiscal 2024. The filing was signed December 14, 2023. Amounts are in U.S. dollars unless stated otherwise.
Business context
BriaCell is a clinical-stage immuno-oncology biotechnology company with no revenue. Its lead Bria-IMT program targets advanced breast cancer; the filing describes a pivotal Phase 3 study as FDA-approved and expected to start before the end of 2023. The company is also developing Bria-OTS and a soluble CD80 therapeutic. On August 31, 2023, it completed a spinout of certain pipeline assets to BriaPro Therapeutics, in which BriaCell retained approximately 66.6% ownership.
Financial performance and position
- Revenue: None reported.
- Operating costs: R&D was $6.86 million, up from $3.26 million; general and administrative expense was $1.65 million, down from $2.15 million. Total operating expenses were $8.50 million versus $5.40 million, producing an operating loss of $8.50 million versus $5.40 million.
- Net result: Net income attributable to BriaCell was $6.00 million, compared with a $1.11 million loss a year earlier. The reported profit largely reflected a $14.28 million gain from the decrease in the fair value of warrant liabilities, rather than operating income. Basic EPS was $0.38; diluted EPS was a loss of $0.50 because the diluted calculation included a warrant-liability adjustment.
- Cash flow: Operating cash use was $7.61 million, compared with $3.54 million in the prior-year quarter. There were no financing cash flows in the quarter. Cash and cash equivalents fell by $7.61 million, from $21.25 million at July 31 to $13.65 million at October 31.
- Liquidity: Working capital was $17.36 million, down from $25.15 million at July 31. Current assets were $18.41 million and current liabilities $1.05 million. Management said existing resources should meet expected liquidity needs for at least 12 months from issuance of the statements.
- Debt and liabilities: The balance sheet reports no debt balance. Current liabilities were $1.05 million; the principal non-current liability was a $15.06 million warrant liability, down from $29.14 million. Total assets were $18.62 million.
- Margins: Not meaningful because the company reported no revenue. The warrant revaluation gain also makes reported net income a poor indicator of operating performance.
Changes versus the prior comparable quarter
- R&D expense more than doubled, driven mainly by higher clinical-trial and investigational-drug costs, increased staffing, and additional preclinical work.
- G&A declined, mainly due to lower share-based compensation.
- Net income improved substantially, primarily because the warrant-liability fair-value gain increased to $14.28 million from $4.12 million. This is a non-operating, non-cash valuation item.
- Cash declined from $21.25 million at the prior fiscal year-end; operating cash use was also higher than in the year-earlier quarter.
Outlook, risks, and unusual items
- Management expects operating losses to continue and says longer-term funding may require additional debt or equity financing. It cautions that financing may not be available on acceptable terms and that failure to raise capital could require spending cuts or curtailment of operations.
- The filing states that Bria-IMT’s Phase 3 study was expected to start before the end of 2023; it does not provide a subsequent confirmation in this report that the study actually started.
- The August 2023 BriaPro spinout transferred specified pipeline assets, including Bria-TILsRx and PKC-delta inhibitors. BriaCell retained control of BriaPro and agreed to provide transition services for a fixed monthly fee of $20,000.
- The company moved from a month-to-month Philadelphia office and lab arrangement to a 12-month lease beginning September 1, 2023, at approximately $36,000 per month.
- Warrant valuation is sensitive to share price and other model assumptions. The filing also identifies foreign-exchange exposure, though management estimated a 5% Canadian-dollar movement would not materially affect results.
- The filing reports no legal proceedings, material changes to previously disclosed risk factors, or off-balance-sheet arrangements. Management concluded disclosure controls were effective at a reasonable-assurance level.
Important facts for investors to verify
- Whether and when the Bria-IMT Phase 3 study began, and its financing, enrollment, and clinical milestones.
- Cash burn and runway, including whether additional financing will be needed sooner than management’s stated 12-month liquidity horizon.
- The composition and valuation sensitivity of the $15.06 million warrant liability and the effect of future fair-value changes on reported earnings.
- BriaPro’s development progress, funding needs, and the value and governance implications of BriaCell’s approximately 66.6% ownership.
- The filing contains inconsistent accumulated-deficit figures: the balance sheet reports $74.65 million, while the MD&A gives $74.56 million in one passage. The balance-sheet figure should be checked against the source statements.